The vaccine stimulates an active immunity against pandemic porcine influenza A/Jena/VI5258/2009 (H1N1)pandemic09-like virus. It induces neutralising and haemagglutination-inhibiting antibodies against this subtype. The antibody responses mentioned in the following have been documented in pigs without maternally-derived immunity. Neutralising antibodies in serum have been detected in more than 75% of the immunised pigs on day 7 after primary immunisation lasting in more than 75% of the pigs for over 3 months. Haemagglutination-inhibiting antibodies have been detected in 15–100% of the immunised pigs on day 7 after primary immunisation which disappeared in the majority of animals within 1 to 4 weeks thereafter.

Efficacy of the vaccine was examined in laboratory challenge studies in pigs without maternally-derived antibodies and was demonstrated against the following strains:

FLUAV/Hamburg/NY1580/2009(H1N1)pdm09 (human origin),

FLUAV/swine/Schallern/IDT19989/2014 (H1N1)pdm09 (swine origin) and

FLUAV/sw/Teo(Spain)/AR641/2016 (H1N1)pdm09 (swine origin).